Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 14,995 Shares

Editas Medicine Inc (NASDAQ:EDIT) insider Katrine Bosley sold 14,995 shares of Editas Medicine stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $34.15, for a total transaction of $512,079.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Katrine Bosley also recently made the following trade(s):

  • On Friday, December 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $29.58, for a total transaction of $246,490.14.
  • On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock. The shares were sold at an average price of $23.64, for a total transaction of $196,992.12.

Editas Medicine Inc (NASDAQ:EDIT) traded down $0.22 on Friday, hitting $33.70. 526,595 shares of the company were exchanged, compared to its average volume of 1,333,454. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. The stock has a market capitalization of $1,500.00 and a P/E ratio of -10.40. Editas Medicine Inc has a one year low of $13.12 and a one year high of $36.00.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). The business had revenue of $6.28 million during the quarter, compared to analysts’ expectations of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The business’s quarterly revenue was up 553.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.59) EPS. research analysts predict that Editas Medicine Inc will post -2.92 EPS for the current fiscal year.

Large investors have recently modified their holdings of the business. First Midwest Bank Trust Division purchased a new position in Editas Medicine during the third quarter valued at approximately $1,349,000. Greenwoods Asset Management Ltd purchased a new position in shares of Editas Medicine in the second quarter worth $1,191,000. American Century Companies Inc. purchased a new position in shares of Editas Medicine in the third quarter worth $7,497,000. Bank of New York Mellon Corp lifted its holdings in shares of Editas Medicine by 123.8% in the second quarter. Bank of New York Mellon Corp now owns 142,122 shares of the company’s stock worth $2,385,000 after buying an additional 78,632 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Editas Medicine in the second quarter worth $285,000. 65.70% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently commented on EDIT. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. ValuEngine cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Monday, November 13th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Editas Medicine has a consensus rating of “Hold” and an average price target of $26.73.

WARNING: This story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3127127/editas-medicine-inc-edit-insider-katrine-bosley-sells-14995-shares.html.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.